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Conducting clinical studies in small populations may be very challenging; therefore quality of
clinical evidence may differ between rare and non-rare disease therapies.
Objective
This register-based study aims to evaluate the characteristics of clinical trials in rare dis-
eases conducted in Latvia and compare them with clinical trials in more common conditions.
Methods
The EU Clinical Trials Register (clinicaltrialsregister.eu) was used to identify interventional
clinical trials related to rare diseases (n = 51) and to compose a control group of clinical trials
in non-rare diseases (n = 102) for further comparison of the trial characteristics.
Results
We found no significant difference in the use of overall survival as a primary endpoint in clini-
cal trials between rare and non-rare diseases (9.8% vs. 13.7%, respectively). However, clin-
ical trials in rare diseases were less likely to be randomized controlled trials (62.7% vs.
83.3%). Rare and non-rare disease clinical trials varied in masking, with rare disease trials
less likely to be double blind (45.1% vs. 63.7%). Active comparators were less frequently
used in rare disease trials (36.4% vs. 58.8% of controlled trials). Clinical trials in rare dis-
eases enrolled fewer participants than those in non-rare diseases: in Latvia (mean 18.3 vs.
40.2 subjects, respectively), in the European Economic Area (mean 181.0 vs. 626.9 sub-
jects), and in the whole clinical trial (mean 335.8 vs. 1406.3 subjects). Although, we found
no significant difference in trial duration between the groups (mean 38.3 vs. 36.4 months).
Conclusions
The current study confirms that clinical trials in rare diseases vary from those in non-rare
conditions, with notable differences in enrollment, randomization, masking, and the use of
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Introduction
Rare diseases are heterogeneous life-threatening or seriously debilitating conditions that affect
less than one person in 2 000 individuals across the European Union (EU) [1]. Most rare dis-
ease patients suffer from ultra-orphan diseases, with a prevalence of less than 1 per 50 000
persons [2]. Development of medicinal products intended for the treatment, diagnosis or pre-
vention of rare diseases (orphan drugs) can be very challenging due to distinct rare disease fea-
tures, such as small patient populations, low event rates, inadequate understanding of disease
natural course, and a lack of previous clinical trials [3]. The most obvious challenge in rare dis-
ease trials is the recruitment of the right patients in adequate numbers [4–6], therefore multi-
center and multinational collaboration is often required.
Drug approval is usually based on a phase III, double blind, randomized, controlled trial
(RCT) widely regarded as the gold standard. However, it may be particularly difficult to use
phase III trial design for evaluating drugs intended to treat rare diseases. For example, phase
III clinical trials supported efficacy for 45% of orphan drug, compared to 73% of non-orphan
drug, US Food and Drug Administration (FDA) approvals for oncological indications [7].
Some orphan drugs were granted marketing approval by the FDA and the European Medi-
cines Agency (EMA) without randomized, doubled blind, placebo controlled pivotal trials [8],
but on the basis of uncontrolled phase II trial, retrospective study, or a literature analysis [9].
Most of the EMA approved orphan drugs demonstrated moderate overall quality of clinical
evidence [10, 11]. The majority of the drugs were tested in trials involving fewer than 200
patients and lasting less than two years [12]. Nearly half of the studies applied some type of
blinding [13] and used placebo as a comparator [12]. RCT are available for approximately 60%
of orphan drugs authorized in the EU [9, 11–14]. Duration of orphan drug trials is often too
short in relation to the natural history of the disease [9, 12, 15]. Dose finding studies and the
use of active comparators are frequently lacking.
An analysis of ClinicalTrials.gov compared interventional clinical trials in rare against non-
rare diseases [16]. Rare disease studies differed to non-rare disease studies across all character-
istics that were examined. Rare disease trials enrolled fewer patients, were longer and more
likely to be early phase, non-randomized, single arm, and open label. A higher proportion of
rare disease trials were multicenter and multinational studies, included pediatric patients, and
were terminated early. However, rare diseases consist of heterogeneous groups of conditions,
which differ in their incidence (ranging from low to relatively high), survival (short vs. long),
and treatment response (small vs. large) [4]. Therefore, clinical trial designs may vary among
different rare diseases. For example, pivotal studies supporting the EMA granted marketing
authorizations of orphan drugs consisted of populations ranging from as few as 7–12 patients
to several hundred patients [4, 13, 14]. Marketing authorizations for oncological orphan drugs
were mostly granted on the basis of large studies in relatively common disorders, whereas
most of those for genetic diseases were based on much smaller studies [4].
Oncology is the major therapeutic area for orphan drugs [17, 18]. Moreover, prevalence of
oncological rare diseases is often higher than that of many non-oncological rare conditions
[11]. It makes oncology a specific rare disease group with a particular interest. Nevertheless,
pivotal trials of orphan drugs approved by the FDA for treatment of cancer related indications
involved less participants, were less likely to be randomized and double blind, but more
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frequently used surrogate primary endpoints and more treated patients had serious adverse
events, compared with pivotal trials used to approve non-orphan cancer drugs [19]. Similarly,
pivotal clinical evidence submitted to the EMA for marketing authorization of oncological
orphan drugs was often limited by low patient numbers, inadequate follow-up, and lack of ran-
domization or blinding [11]. Although, RCT data were provided in 57% of the studies.
Another study, focusing on non-cancer orphan drugs approved by the FDA, found that
orphan drugs had fewer pivotal clinical trials and fewer participants, but development times,
proportions with randomization, blinding, and use of placebo and clinically relevant endpoints
were similar between orphan and non-orphan drugs [20]. In neurological diseases, all drugs
approved by the FDA without an orphan indication included at least two double blind RCT,
compared to 32% of drugs with an orphan indication [8]. Though, 74% of orphan drugs had at
least one such trial. Additionally, orphan drugs had less pivotal trials per drug and smaller trial
sizes than non-orphan drugs.
Therapies for lysosomal storage disorders (mostly enzyme replacement therapies) were
approved by the FDA mainly based on small clinical trials, with either surrogate or biomarker
endpoints (e.g. in Gaucher disease, Fabry disease, and cystinosis) [21]. Identification of the most
appropriate primary endpoint and target population of a pivotal clinical trial is crucial for suc-
cessful marketing approval of orphan drugs [22]. Ideally, if appropriate hard clinical endpoint
exists, it should be preferred [3, 23]. However, if the clinically meaningful (hard) primary end-
point (such as overall survival) is chosen, the small sample size or limited trial duration may not
be adequate to demonstrate statistical significance [13, 22]. When the use of hard clinical end-
points is impossible or impractical, then surrogate endpoints can be considered, but need to be
fully justified [3, 23]. A number of drugs for the treatment of rare diseases have been approved
using surrogate endpoints, which are generally often used in clinical studies of orphan drugs, in
contrast to quality of life (QoL) related endpoints and hard clinical endpoints. For example, in
the EU, less than 30% of orphan drug pivotal studies included a QoL-related endpoint and less
than 20% of the studies used at least one hard primary endpoint [13]. Especially for some ultra-
rare disorders, surrogate endpoints are a necessary part of drug development process [24].
Apparently, limited data from pivotal trials of orphan drugs, coupled with usually high
drug costs, may create obstacles in reimbursement and market access of these products [11,
17, 25]. Though, in Belgium, orphan drugs are more likely to be reimbursed despite lower
quality of clinical evidence [15]. Latvia is known to be a small market with restricted availabil-
ity and accessibility of orphan drugs [17, 25]. However, clinical trials in rare diseases have not
been studied there. Clinical studies can allow rare disease patients access to investigational
drugs, while the quality of data from these studies may affect reimbursement decisions and fur-
ther market access of rare disease therapies. The current study aims to evaluate the characteris-
tics of clinical trials in rare diseases conducted in Latvia and compare them with clinical trials
in more common conditions.
Materials and methods
EU Clinical Trials Register
We used the EU Clinical Trials Register (clinicaltrialsregister.eu) to identify clinical trials
related to rare diseases and to compose a control group of clinical trials in non-rare diseases
for further comparison of the trial characteristics. The register contains information on inter-
ventional clinical trials on medicines conducted in the EU, or the European Economic Area
(EEA), which started after 1 May 2004. The present study was performed in May 2016, cover-
ing a period of 12 years. The EU Clinical Trials Register provides the public with information
held in the EU clinical trials database (EudraCT). The EudraCT database is maintained by the
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EMA and used by the national competent authorities to enter clinical trial data, originally pro-
vided by the sponsor, and to support supervision of clinical trials.
Search strategy
Advanced search tools (filters) were used to restrict the search to clinical trials related to rare
diseases which were conducted in Latvia. The search filters used included: “Country—Latvia”,
“Rare disease”, and “Investigational medicinal product (IMP) with orphan designation in the
indication”. A total of 51 clinical trials with a unique EudraCT number, which identifies the
trial throughout its lifespan, were identified (S1 Appendix). The detailed trial protocol-related
data were accessed through the Organization for Standardization (ISO) code for Latvia (LV).
Data displayed for some clinical trials were incomplete or contained inconsistencies. For the
missing information of such trials, we used data provided by other EEA countries (via the clin-
icaltrialsregister.eu) and/ or ClinicalTrials.gov (a clinical trials database maintained by the US
National Library of Medicine at the National Institutes of Health). The following characteris-
tics of the trials were analyzed: primary endpoints, randomization, masking, comparators, esti-
mated trial enrollment and duration.
Control group
For the control group of clinical trials in non-rare diseases, 376 unique clinical studies in com-
mon conditions conducted in Latvia were initially classified by therapeutic areas and trial
phases. Then, 102 clinical trials were randomly chosen to compose the control group (S2
Appendix). Ratio of the control group clinical trials to rare disease clinical trials was 2:1. Pro-
portions of therapeutic areas and trial phases were maintained between the two groups for
comparability reasons. Therapeutic areas of clinical trials in the control group were distributed
as follows: oncology—40 trials (39.2%); infections—20 trials (19.6%); endocrine and metabolic
diseases—18 trials (17.6%); nervous system—6 trials (5.9%); blood diseases—6 trials (5.9%);
circulatory system—4 trials (3.9%); respiratory system—4 trials (3.9%); and digestive system—
4 trials (3.9%). 66 clinical trials (64.7%) were phase III trials, 28 (27.5%) were phase II trials,
and 8 (7.8%) were phase IV trials.
Primary endpoints
We analyzed whether overall survival (OS) was used as one of the primary endpoints in clinical
trials. Outcome measures other than OS were classified as non-OS. Examples of such end-
points included disease-specific mortality, morbidity, clinical events, hospitalization, patient
reported outcomes (symptoms, functioning, health-related QoL), physical signs, laboratory
measures, biomarkers, radiological tests, response rates, progression-free survival (PFS), dis-
ease-free survival (DFS), pharmacokinetic (PK) parameters, and adverse events (AE). Only the
primary endpoints were evaluated; secondary endpoints were not taken into account.
Comparators
Controls (comparators) were classified into the following types: placebo, different (active)
treatment, different dose or regimen of the study drug (dose comparison), no treatment, or
external (historical) control [26].
Data analysis
We used Fisher’s exact test for statistical analysis of categorical variables: primary endpoints,
randomization, masking, and comparators. T-test was used for scalar values: estimated trial
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duration and enrollment (S3 Appendix). 5% was used as a significance level of the tests, con-
sidering that with p<0.05 the null hypothesis could be rejected.
Results
Clinical trials in rare diseases
A total of 51 interventional clinical trials related to rare diseases, which were conducted in Lat-
via, were identified through the EU Clinical Trials Register (Table 1). 28 trials (54.9%) involved
IMP with orphan designation in the studied indication. A total of 35 unique IMP were studied
in 29 different rare conditions. Oncology was the biggest therapeutic area, with 20 clinical tri-
als (39.2%), followed by infections, with 10 trials (19.6%), and endocrine and metabolic dis-
eases, with 9 trials (17.6%). Multidrug-resistant tuberculosis (MDR-TB) was the most studied
condition, with 7 trials (13.7%), followed by chronic lymphocytic leukemia (CLL), with 4 trials
(7.8%), and chronic myelogenous leukemia (Ph+ CML), acromegaly, and pseudomonas aeru-
ginosa infection in cystic fibrosis, with 3 trials (5.9%) in each condition. 33 clinical trials
(64.7%) were phase III trials (including two phase II/III trials), 14 (27.5%) were phase II trials,
and 4 (7.8%) were phase IV trials.
Characteristics of clinical trials in rare vs. common diseases
We found no significant difference in the use of OS as a primary endpoint in clinical trials
between rare and non-rare diseases (9.8% vs. 13.7%, respectively; p = 0.608) (Fig 1A). How-
ever, clinical trials in rare diseases were less likely to be randomized controlled trials (62.7% vs.
83.3%; p = 0.008) (Fig 1B). Rare and non-rare disease clinical trials varied in masking, with
rare disease trials less likely to be double blind (45.1% vs. 63.7%; p = 0.035) (Fig 1C). Active
comparators were less frequently used in rare disease trials (36.4% vs. 58.8% of controlled tri-
als; at a significance level of 10%, as Fisher’s exact test p = 0.052) (Fig 1D). Clinical trials in rare
diseases enrolled fewer participants than those in non-rare diseases: in Latvia (mean 18.3 vs.
40.2 subjects; 95% confidence interval (CI) of the difference 9.8–33.9; p = 0.014) (Fig 2A), in
the EEA (mean 181.0 vs. 626.9 subjects; 95% CI 239.3–652.5; p<0.001) (Fig 2B), and in the
whole clinical trial (mean 335.8 vs. 1406.3 subjects; 95% CI 548.0–1593.0; p<0.001) (Fig 2C).
Although, we found no significant difference in trial duration between the groups (mean 38.3
vs. 36.4 months; 95% CI -10.9–7.1; p = 0.652) (Fig 2D). All studies included in the analysis
were multicenter and multinational trials involving multiple EEA member states and/ or being
conducted both within and outside the EEA.
Discussion
According to Lithuanian study published in 2008, shortly after joining the EU, the number of
clinical trials aimed at orphan drugs remained low in the Baltic States [27]. Between May 2004
and June 2007, four clinical trials on orphan medicinal products were approved in Lithuania,
one trial in Estonia, and no trials in Latvia. The current study covered a period of time between
May 2004 and May 2016 and included both orphan drugs and non-orphan drugs for rare dis-
eases. As a result, 51 clinical trials in rare diseases were identified in Latvia. More than half of
them (28 trials) involved orphan medicinal products, indicating that the number of clinical tri-
als for orphan drugs has notably increased in recent years. It should be pointed out, however,
that the principal investigators of all of the studies described in the current analysis were not
from Latvia, but centers in our country provided sites/ patients to these trials. In fact, none of
the trial sponsors was from Latvia or other Baltic States. This applied to both, clinical trials in
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Table 1. Clinical trials in rare diseases.
INN (trade name/
code name)







Bedaquiline (Sirturo) MDR-TB Phase II, RCT,
double blind
Placebo SCC 58 15 15 150
Bedaquiline (Sirturo) MDR-TB Phase II, open
label
SCC 40.5 13 23 225
Bedaquiline (Sirturo) MDR-TB Phase III,
RCT, double
blind
Placebo SCC 66 7 13 600
Delamanid (Deltyba) MDR-TB Phase II, RCT,
double blind
Placebo SCC; PK; AE 10 13 26 201
Delamanid (Deltyba) MDR-TB Phase II, open
label extension
AE 14 80 100 430
Delamanid (Deltyba) MDR-TB Phase II, open
label
AE; PK 17 20 30 30
Delamanid (Deltyba) MDR-TB Phase III,
RCT, double
blind
Placebo SCC 59 60 150 390
Dopastatin (BIM-
23A760)
Acromegaly Phase II, open
label
GH levels 8 10 24 24
Dopastatin (BIM-
23A760)
Acromegaly Phase II, open
label
GH and IGF-1 levels 14 5 60 80
Dopastatin (BIM-
23A760)
Carcinoid syndrome Phase II, open
label
Symptom relief (diarrhea and/
or flushes)



































Placebo Development of pancreatic or
peripancreatic infection


































Injection intervals (6 or 8
weeks) based on IGF-1 levels
24 20 110 150
Lanreotide
(Somatuline)
Carcinoid syndrome Phase IV,
RCT, double
blind
Placebo Usage of s/c octreotide as
rescue medication to control
symptoms (diarrhea and/ or
flushing)









Placebo CFA; CNA; stool parameters;
nutritional parameters; clinical
symptomatology; AE
6 30 60 80
(Continued)
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OS; PFS 48 40 834 834
Catumaxomab
(Removab)
Malignant ascites Phase II/III,
RCT, open
label





























Placebo Total daily insulin dose;
HbA1c levels
36 25 385 530
Bosutinib (Bosulif) Ph+ CML Phase III,
RCT, open
label
Imatinib (Glivec) Complete cytogenetic
response rate
108 30 206 412
Bosutinib (Bosulif) Ph+ CML Phase III,
open label
extension
AE (with special focus on
diarrhea); BCR-ABL
mutations; OS
84 2 136 500
Ciprofloxacin DPI
(BAYQ3939)
Non-CF bronchiectasis Phase III,
RCT, double
blind
Placebo Frequency of pulmonary
exacerbations
34 28 200 400
Ciprofloxacin DPI
(BAYQ3939)
Non-CF bronchiectasis Phase III,
RCT, double
blind
Placebo Frequency of pulmonary
exacerbations
28 28 172 400
Duvelisib (IPI-145) CLL/SLL Phase III,
RCT, open
label
Ofatumumab (Arzerra) PFS 72 22 174 307
Duvelisib (IPI-145) CLL/SLL Phase III,
open label
extension
Ofatumumab (Arzerra) Overall response rate 24 22 174 307
Pazopanib (Votrient) Renal cell carcinoma Phase III,
RCT, double
blind
Placebo PFS 24 10 175 400
Pazopanib (Votrient) Renal cell carcinoma Phase III,
open label
extension
AE 24 3 98 145



















48 25 350 650
Eprodisate disodium
(Kiacta)
AA amyloidosis Phase III,
RCT, double
blind
Placebo CrCl; SCr; progression to end-
stage renal disease





AE 55 7 560 800
Eltrombopag
(Revolade)
ITP Phase II, RCT,
double blind
Placebo Platelet count 18 10 129 422
(Continued)
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rare and non-rare diseases, which were almost exclusively sponsored by global commercial
pharmaceutical companies. There was only one non-commercial sponsor in each group.
The majority of rare disease clinical studies were phase III studies, while oncology was the
biggest therapeutic area, followed by infections and endocrine and metabolic diseases. Onco-
















Ofatumumab (Arzerra) PFS 38 8 225 466
Lapatinib (Tyverb) Squamous cell





Placebo DFS 27 4 422 680




AE 24 1 4 10
Masitinib (AB1010) Mastocytosis Phase III,
RCT, double
blind
Placebo Symptom relief (pruritus,
flushes, depression, and
asthenia)
42 15 170 200
Octocog alfa (BAY 81–
8973)
Hemophilia A Phase III,
open label











21 15 620 1146
Brivaracetam
(Briviact)
Focal epilepsy/ POS Phase III,
RCT, double
blind
Placebo POS (type I seizures)
frequency
43 40 350 900
Brivaracetam
(Briviact)
Focal epilepsy/ POS Phase III,
open label
extension
AE 68 40 274 720
Nilotinib (Tasigna) Ph+ CML Phase III,
open label
Rate of molecular response 48 8 743 806
Ibandronic acid
(Bondronat)





Skeletal related events 36 25 424 424
Turoctocog alfa
(NovoEight)
Hemophilia A Phase III,
open label
extension
Frequency of development of
FVIII inhibitors
90 8 36 215














Placebo PFS; OS 47 24 224 420
INN, international nonproprietary name; CT, clinical trial; EEA, European Economic Area; MDR-TB, multidrug-resistant tuberculosis; RCT, randomized controlled
trial; SCC, sputum culture conversion; PK, pharmacokinetics; AE, adverse events; GH, growth hormone; IGF-1, insulin-like growth factor-1; CF, cystic fibrosis; FEV1,
forced expiratory volume in one second; PFS, progression-free survival; s/c, subcutaneous; CFA, coefficient of fat absorption; CNA, coefficient of nitrogen absorption;
OS, overall survival; SOC, standard of care; HbA1c, hemoglobin A1c (glycated hemoglobin); Ph+ CML, Philadelphia chromosome positive chronic myelogenous
leukemia; DPI, dry powder for inhalation; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; tid, three times a day; 6MWT, six-minute walk test;
CA-125, cancer antigen 125; CrCl, creatinine clearance; SCr, serum creatinine; ITP, immune (idiopathic) thrombocytopenic purpura; DFS, disease-free survival; POS,
partial onset seizure; FVIII, coagulation factor 8; IFN β-1a, interferon beta-1a.
https://doi.org/10.1371/journal.pone.0194494.t001
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orphan drugs [17, 18]. The finding that infectious diseases made the second largest therapeutic
area in our study can be explained by the fact that MDR-TB was the most studied condition.
In fact, the three Baltic States are classified as MDR-TB high burden (high priority) countries
with the highest prevalence of MDR-TB in the EU/EEA [28]. In addition, these countries have
established high quality surveillance systems to monitor drug resistance. Disease prevalence as
well as diagnostic and treatment options of rare diseases may vary between different EU coun-
tries. In this context, conducting clinical studies in MDR-TB in the Baltic States seems rational,
as appropriate patients are concentrated there in relatively high numbers.
Our findings are consistent with the previous studies reporting that RCT are available for
approximately 60% of rare disease therapies [9, 11–14] and that significant differences exist in
enrollment, randomization, blinding, and the use of active comparators between clinical trials
in rare and non-rare conditions [8, 11, 15, 16, 19]. As might be expected, clinical trials in rare
diseases recruited fewer participants. This is in line with the recent investigation by Hee et al.
[29], who examined the association between the disease prevalence and sample size for inter-
ventional clinical trials in rare diseases and found that trials of rarer diseases were noticeably
smaller than the less rare diseases trials (generally sample size increases as prevalence
Fig 1. Characteristics of clinical trials in rare vs. non-rare diseases. (A) Primary endpoints. (B) Randomization. (C) Masking. (D) Comparators.
https://doi.org/10.1371/journal.pone.0194494.g001
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increases). The authors were surprised that a majority of trials were conducted in one country
only, regardless of the disease prevalence, given the opportunity to recruit more patients in
multinational studies. Although, Bell and Tudur Smith [16] found that a higher proportion of
rare disease trials were multicenter and multinational studies compared to non-rare disease
studies. In the current analysis, all clinical trials were multinational studies involving multiple
EEA member states and/ or being conducted both within and outside the EEA. One might log-
ically expect longer trials in rare diseases (as found by Bell and Tudur Smith [16]) to compen-
sate for few participants in order to demonstrate statistical significance, but this was not
confirmed in the current study. One might also expect more sophisticated statistical modeling,
which does not seem to be true empirically [30]. Unkel et al. reviewed the methods used to
evaluate therapies in two rare conditions (paediatric multiple sclerosis and Creutzfeldt-Jakob
disease) and found that the statistical methodology used was fairly basic. This applied in
Fig 2. Estimated trial enrollment and duration. (A) Enrollment in Latvia. (B) Enrollment in the EEA. (C) Enrollment in the whole clinical trial. (D) Trial duration.
https://doi.org/10.1371/journal.pone.0194494.g002
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particular to paediatric multiple sclerosis, for which the evidence on therapeutic interventions
was almost exclusively based on observational studies. Studies of this type might have special
importance for rare diseases, as large sample size is not readily available for trials in these con-
ditions [6, 14, 31], though observational studies were out of the scope of the current analysis,
which was aimed at interventional studies only.
The current study has certain limitations. Firstly, we analyzed all (completed and ongoing)
interventional clinical trials related to all rare diseases and orphan drugs (authorized and not
authorized). In contrast, most previous studies (except the analysis of ClinicalTrials.gov [16])
were restricted to specific therapeutic areas, such as oncology or neurology, and/ or assessed
only pivotal clinical trials (primarily supporting efficacy) of authorized orphan drugs [7, 8, 11,
13, 19–21, 32]. Secondly, this is a register-based study. Bell and Tudur Smith carried out the
US register-based analysis of ClinicalTrials.gov [16] (the work extended later by Hee et al. [29],
but without comparison between rare and non-rare disease trials), described a number of limi-
tations of the dataset and pointed out that other registers, such as clinicaltrialsregister.eu, can
also be used. In the EU Clinical Trials Register, a trial protocol reports the estimated enroll-
ment, rather than the actual number of patients recruited. The expected numbers of patients
to be enrolled in clinical trials may be overestimated [29]. For example, in the above men-
tioned analysis of ClinicalTrials.gov [16], the actual enrollment in rare disease trials was 70.1%
of the anticipated enrollment, compared to 81.6% in non-rare disease trials.
The EU Clinical Trials Register contains information on clinical trials, which started after
May 2004, while the orphan drug regulation 141/2000 was introduced in the EU in 2000 [1].
Trials started before the implementation of the clinical trial directive 2001/20/EC in 2004 [33]
are not listed in the register. Moreover, in March 2011, version 8.0 of the EudraCT database
was launched putting in place a more comprehensive set of validation rules for data entry. His-
torical data, entered into the database between May 2004 and March 2011, may be incomplete
or contain inconsistencies, due to less stringent requirements for data entry, or absence of
some fields in earlier versions of EudraCT. In addition, research and regulatory procedures
alter over time. Potentially less rigorous evaluation criteria might have been used for older
therapies than for recently approved ones. Information can also be missing because data have
not been provided by the sponsor. However, these limitations seem to apply equally to both,
rare and non-rare disease clinical trials, and are not likely to cause a bias.
Conclusions
Quality of clinical evidence is affected by numerous challenges faced by investigational drugs
for rare diseases. Despite the fact that RCT are available for over 60% of rare disease therapies,
clinical trials in rare diseases vary from those in non-rare conditions. Clinical studies in
orphan diseases enroll fewer participants and are less likely to use randomization, blinding,
and active comparators. However, we found no significant difference in trial duration and the
use of overall survival as a primary endpoint.
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